Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy

Area of Science:

• Oncology
• Nanotechnology
• Pharmaceutical Sciences

Background:

• Liposomal drug delivery systems offer significant potential in cancer treatment.
• Clinical application of liposomal formulations is hindered by various limiting factors.
• A notable discrepancy exists between experimental findings and clinical outcomes for liposomes.

Purpose of the Study:

• To review and identify barriers limiting the clinical translation of liposomal delivery systems in cancer therapy.
• To analyze the differences between preclinical and clinical studies of liposomal formulations.
• To propose potential strategies for overcoming challenges in the clinical application of liposomal drug delivery.

Main Methods:

• Literature review focusing on liposomal formulations in cancer therapy.
• Comparative analysis of preclinical (in vitro and in vivo) and clinical study data.
• Identification and discussion of key translational barriers.

Main Results:

• Significant differences exist in formulation, administration, and biological environment between preclinical models and human patients.
• Factors such as immunogenicity, stability, and off-target toxicity contribute to clinical limitations.
• Preclinical efficacy does not always translate to clinical benefit due to these discrepancies.

Conclusions:

• Addressing the identified preclinical-clinical gap is crucial for successful liposomal cancer therapy.
• Strategies include optimizing liposome design, improving preclinical models, and careful clinical trial design.
• Overcoming these barriers will enhance the therapeutic potential of liposomal drug delivery systems in oncology.